Alligator Bioscience has reported updated results with its CD40 agonist mitazalimab as a first-line treatment for advanced pancreatic cancer, a disease with few treatment options.<
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
